#2249
Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction:
The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Davi' M
Authors:
Zambon G,
Cosaro E,
Cingarlini S,
Trombetta M,
Landoni L,
Keywords:
pasireotide,
malignant insulinoma,
hypoglycemia,
#1447
Clinicopathologic Features, Management and Outcome of Neuroendocrine Tumors (NETs) in MEN1: The Verona Multidisciplinary PlaNET Group
Introduction:
Gastroenteropancreatic endocrine tumors (GEP-NETs) are a frequent manifestation of MEN1. They represent an important prognostic factor in these patients. There is still a debate on their management, mainly on surgical strategy, due to their multicentricity and high recurrence rate.
Conference:
13th Annual ENETSConcerence (2016)
Presenting Author:
Authors:
Cosaro E,
Mella A,
Cingarlini S,
Grego E,
Ortolani S,
Keywords:
MEN1,
GEP-NET,
management,
#1226
Follow Up of ≤ 2 cm Non Functioning Pancreatic NETs in Patients with MEN1 Treated with Conservative Approach
Introduction:
There is a current trend for conservative treatment of non functioning pancreatic NET (NF-PNETs), ≤ 2 cm, in patients with MEN1, which are reported to be associated with low risk of metastasis and death.
Conference:
12th Annual ENETSConcerence (2015)
Presenting Author:
Davi' M
Authors:
Davì M,
Cosaro E,
Malpaga A,
Butturini G,
Ortolani S,
Keywords:
Pancreatic neuroendocrine tumor,
MEN1,
